Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa
収録刊行物
-
- Clin Endocrinol (Oxf)
-
Clin Endocrinol (Oxf) 67 (2), 282-289, 2007